Healthcare Decliners: Aldeyra Therapeutics (NASDAQ:ALDX), Ignyta (NASDAQ:RXDX), Vital Therapies (NASDAQ:VTL), Actinium (NYSEMKT:ATNM), TrovaGene (NASDAQ:TROV)

Technology Stocks News 15

Aldeyra Therapeutics Inc (NASDAQ:ALDX) quiet period is set to expire on Wednesday, June 11th. Aldeyra Therapeutics had issued 1,500,000 shares in its IPO on May 2nd, AR Network reports. The total size of the offering was $12,000,000 based on an initial share price of $8.00. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -7.08% in last session and finished the day at $6.69. Traded volume was 26,246.00million shares in the last session and the average volume of the stock remained 26.32K shares. Aldeyra Therapeutics Inc (NASDAQ:ALDX) insider ownership is 1.20%.

Ignyta, Inc. (NASDAQ:RXDX), an oncology precision medicine biotechnology company, announced on 01 June 2014 that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Ignyta Inc (NASDAQ:RXDX) dropped -9.57 percent to $8.22 Wednesday on volume of 36,522.00million shares. The intra-day range of the stock was $8.07 to $9.10. Ignyta Inc (NASDAQ:RXDX) has a market capitalization of $160.94million.

Vital Therapies Inc (NASDAQ:VTL) currently has a Zacks Rank #3 (Hold). Vital Therapies Inc (NASDAQ:VTL)’s stock on June 18, 2014 reported a decrease of -5.83% to the closing price of $30.52. Its fifty two weeks range is $10.66 -$35.20. The total market capitalization recorded $665.05million. The overall volume in the last trading session was 94,035.00million shares. In its share capital, VTL has 21.12million outstanding shares.

Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is set to join the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. On Wednesday, shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) dropped -6.33% to close the day at $10.35. Company return on investment (ROI) is 850.80% and its monthly performance is recorded as 4.65%. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) quarterly revenue growth is 26.37%.

Trovagene, Inc. (NASDAQ:TROV) on 16 June 2014 announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. TrovaGene Inc (NASDAQ:TROV) stock performance was -5.45% in last session and finished the day at $3.64. Traded volume was 108,580.00million shares in the last session and the average volume of the stock remained 68.67K shares. The beta of the stock remained -0.91. TrovaGene Inc (NASDAQ:TROV) insider ownership is 14.93%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone